All
Investigational Therapy Granted Breakthrough Designation for Lung Cancer Subset
December 21st 2020The decision was based on data that demonstrated sotorasib induced anticancer activity and achieved a positive benefit-risk profile in patients with locally advanced or metastatic non-small cell lung cancer whose disease harbors a KRAS G12C mutation.
FDA Approves Iclusig for Adult Patients with Resistant/Intolerant Chronic-Phase CML
December 19th 2020The Food and Drug Administration approved the supplemental new drug application for Iclusig (ponatinib) to treat patients with chronic-phase chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors.
FDA Approves Tagrisso as Adjuvant Therapy for Non-Small Cell Lung Cancer After Tumor Resection
December 18th 2020This approval allows Tagrisso to be used after tumor resection in non-small cell lung cancer patients with tumors that have certain epidermal growth factor receptor mutations or deletions.
FDA Approves Xpovio for Use with Velcade and Dexamethasone in Multiple Myeloma
December 18th 2020This treatment regimen of Xpovio with Velcade, approved for patients with multiple myeloma previously treated with at least one therapy, provides another option for patients with multiple myeloma to potentially close the treatment gap.
What Patients with Cholangiocarcinoma Should Be Prepared for When Joining a Trial
December 17th 2020A clinical research coordinator discusses how patients with cholangiocarcinoma can get involved in clinical trials, such as the phase 3 PROOF trial, as well as what they should know once they are enrolled.